Give negative trials plenary slots at the big cancer conferences
Conferences headline the trials that worked. A dedicated plenary for important trials that failed would make the lessons impossible to miss.
Practice-changing negative trials (for example those that stop an established practice) are sometimes presented, but most negative trials are relegated to posters or never submitted. A standing plenary session at ASCO, ESMO and AACR for high-importance negative and reversal trials, with a discussant focused on lessons for design and biology, would raise the status of reporting failure.
- Failures are hidden · Negative trials, failed drugs and abandoned programmes are rarely published, so the same mistakes are repeated.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
Pages like this
not linked directly; found by shared links- IdeaEnd the abstract-to-paper gap: require full results with any conference presentation
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Failures are hidden, Knowledge reaches practice too slowly.
- IdeaMicro-learning pushed to community oncologists within 30 days of a practice change
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaLiving, machine-readable guidelines pushed to the point of care in every country
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaA guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaCap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO).
- IdeaFund investigators from under-represented communities and community sites to lead trials
Shares American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO).
- IdeaOpen licences for publicly funded cancer guidelines
Shares European Society for Medical Oncology (ESMO), Knowledge reaches practice too slowly.
- IdeaOffline decision support for generalists treating common cancers in low-resource settings
Shares American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.